Pfizer and BioNTech on Monday submitted preliminary clinical data to US health authorities as part of their effort to seek authorization for a third dose of their COVID-19 vaccine for all Americans, AFP reports.
The two companies presented the results of their Phase One trial that evaluated the safety and efficacy of a third shot.